Cytomx Therapeutics Inc Stock Price, News & Analysis

CytomX Therapeutics (CTMX) reported strong advancements in its clinical pipeline, highlighted by a three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) for breast cancer. The company also continues to enroll patients in the CX-2029 Phase 2 expansion study across four cancer types in collaboration with AbbVie, and Bristol Myers Squibb has expanded its Probody Program into three additional cancer types. In 2020, total revenues reached $100.4 million, up from $57.5 million in 2019, with cash reserves at $316.1 million. The company aims to report initial Phase 2 data in Q4 2021.

CytomX Therapeutics, focused on oncology, announced CEO Sean McCarthy's participation in March virtual healthcare conferences. Key events include the Cowen 41st Annual Virtual Health Care Conference on March 1, 2021, from 1:20-2:20 p.m. ET, and the Barclays Global Virtual Healthcare Conference on March 10, 2021, from 4:45-5:10 p.m. ET. A webcast of the Barclays presentation will be available on CytomX's website, with an archived replay accessible for 90 days. CytomX is pioneering the Probody® technology, developing therapies aimed at more effective cancer treatment.

CytomX Therapeutics (Nasdaq: CTMX) has announced the grant of stock options to a new employee, totaling 65,000 shares at an exercise price of $8.64, aligning with the closing stock price on February 16, 2021. This option issuance is part of the 2019 Employment Inducement Incentive Plan, which aims to attract new talent to the company. CytomX specializes in developing a unique class of antibody therapeutics based on its Probody technology platform, focused on treating cancer more safely and effectively.

CytomX Therapeutics (Nasdaq: CTMX) announced plans to report its fourth quarter and full-year financial results for 2020 on February 24, 2021, after U.S. market close. A conference call will be held at 5:00 p.m. ET to discuss these results and the company's corporate update. CytomX specializes in conditionally-active antibody therapeutics to treat cancer, with a focus on its Probody technology platform. The company is involved in multiple collaborations and has a pipeline featuring several clinical-stage assets, including therapies against difficult-to-drug cancer targets.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced participation by CEO Sean McCarthy in a virtual fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 3:30 p.m. ET. The event will feature one-on-one meetings with investors. Interested parties can access the live webcast on CytomX's website, with archives available for 90 days post-event. CytomX focuses on developing investigational antibody therapeutics utilizing its Probody technology platform for safer cancer treatments, including candidates targeting previously undruggable targets.

CytomX Therapeutics (CTMX) announced the sale of an additional 2,142,857 shares of common stock through underwriters’ option, totaling 16,428,571 shares sold at $7.00 each. This public offering generated approximately $107.7 million in net proceeds after expenses. J.P. Morgan, Cowen, and Piper Sandler managed the offering. The funds will support CytomX's development of Probody® therapeutics targeting cancer. The offering was registered with the SEC, and details are available on their website.

CytomX Therapeutics (CTMX) has completed its underwritten public offering, selling an additional 2,142,857 shares of common stock for a total of 16,428,571 shares at $7.00 each. This resulted in net proceeds of approximately $107.7 million after deducting expenses. The offering was managed by J.P. Morgan, Cowen, and Piper Sandler. The securities were offered under an effective SEC registration statement. CytomX focuses on innovating safer cancer therapies using its Probody technology, aiming to target previously undruggable cancer types.

CytomX Therapeutics (CTMX) has completed its underwritten public offering of 14,285,714 shares at $7.00 per share, generating approximately $93.6 million in net proceeds. The offering was entirely sold by CytomX, which has also granted underwriters a 30-day option to purchase an additional 2,142,857 shares at the same price. The offering was conducted under an SEC registration statement filed in November 2018. The proceeds will be utilized to support the company’s ongoing development of cancer therapies utilizing its Probody technology platform.

CytomX Therapeutics (CTMX) has announced a public offering of 14,285,714 shares at $7.00 each, aiming for gross proceeds of $100 million before expenses. The company intends to allocate the proceeds toward the advancement of its Probody therapeutics pipeline, particularly for ongoing Phase 2 studies of CX-2009 and CX-2029. The offering is set to close around January 25, 2021, subject to customary conditions. This financial move reflects CytomX's commitment to developing innovative cancer treatments through its proprietary technology.